Furthermore, we also demonstrated a reasonable strategy for upregulating cell surface expression of HLA-G on tumor cells via pretreatment with low-dose chemotherapeutic agents; this pretreatment maximizes the antitumor efficacy of the CAR-NK cells both in vitro and in vivo. The gene discussed is HLA-G; the disease is neoplasm.